Download PDF
Semin Reprod Med 2000; 18(4): 433-440
DOI: 10.1055/s-2000-13733
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Recurrent Pregnancy Loss: Summary and Clinical Recommendations

Richard M. Lee1 , Robert M. Silver2
  • 1Department of Obstetrics & Gynecology, UC Irvine, Orange, California
  • 2Department of Obstetrics & Gynecology, University of Utah, Salt Lake City, Utah
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

Recurrent pregnancy loss (RPL) is traditionally defined as three or more consecutive pregnancy losses before 20 weeks of gestation. This problem occurs in approximately 1% of all couples and is a frustrating problem for both the patient and physician. This article provides an overview of the problem, including causes, treatments, and recommendations. Among the numerous proposed causes of RPL, only parental karyotype abnormalities, antiphospholipid syndrome, uterine malformations, and cervical incompetence are universally accepted. There are numerous treatments for RPL, but only the efficacy of heparin and low-dose aspirin in women with antiphospholipid syndrome has been established with properly controlled trials. Even after undertaking a complete evaluation, the cause of RPL remains uncertain in over 50% of cases. These patients should understand that subsequent pregnancies have up to a 70% chance of success without treatment.

KEYWORD

Recurrent pregnancy loss - recurrent miscarriage - habitual abortion

REFERENCES

  • 1 Coulam C B. Epidemiology of recurrent spontaneous abortion.  Am J Reprod Immunol . 1991;  26 23-27
    PubMedGoogle Scholar
  • 2 Hill J A. Sporadic and recurrent spontaneous abortion.  Curr Prob Obstet Gynecol Fertil . 1994;  17 114-162
    PubMedGoogle Scholar
  • 3 Byrne J LB, Ward K. Genetic factors in recurrent abortion.  Clin Obstet Gynecol . 1994;  37 693-704
    PubMedGoogle Scholar
  • 4 Portnoi M F, Joye N, Van Den Akker J. Karyotypes of 1142 couples with recurrent abortion.  Obstet Gynecol . 1988;  72 31-34
    PubMedGoogle Scholar
  • 5 Simpson J L, Elias S, Martin A O. Parental chromosome rearrangements associated with repetitive spontaneous abortion.  Fertil Steril . 1981;  36 584-590
    PubMedGoogle Scholar
  • 6 ACOG Technical Bulletin Number 212. Early pregnancy loss. September 1995
    Google Scholar
  • 7 Hassold T J. A cytogenetic study of repeated spontaneous abortions.  Am J Hum Genet . 1980;  32 723-730
    PubMedGoogle Scholar
  • 8 Warburton D, Kline J, Stein Z, Hutzler M, Chin A, Hassold T. Does the karyotype of a spontaneous abortion predict the karyotype of a subsequent abortion?.  <~>Evidence from 273 women with two karyotyped spontaneous abortions. Am J Hum Genet . 1987;  41 465-483
    PubMedGoogle Scholar
  • 9 Byrne J, Warburton D, Kline J, Blanc W, Stein Z. Morphology of early fetal deaths and their chromosomal characteristics.  Teratology . 1985;  32 297-315
    CrossrefPubMedGoogle Scholar
  • 10 Daya S, Ward S, Burrows E. Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatments in patients with recurrent spontaneous abortion.  Am J Obstet Gynecol . 1988;  158 225-232
    PubMedGoogle Scholar
  • 11 Karamardian L M, Grimes D A. Luteal phase deficiency: effect of treatment on pregnancy rates.  Am J Obstet Gynecol . 1992;  167 1391-1398
    PubMedGoogle Scholar
  • 12 Goldstein P, Berrier J, Rosen S, Sacks H S, Chalmers T C. A meta-analysis of randomized control trials of progestational agents in pregnancy.  Br J Obstet Gynaecol . 1989;  96 265-274
    CrossrefPubMedGoogle Scholar
  • 13 Noyes R W, Hertig A TR, Rock J. Dating the endometrial biopsy.  Fertil Steril . 1975;  122 262-263
    PubMedGoogle Scholar
  • 14 Davis O K, Berkeley A S, Naus G J, Cholst I N, Freedman K S. The incidence of luteal phase defect in normal, fertile women, determined by serial endometrial biopsy.  Fertil Steril . 1989;  51 582-586
    PubMedGoogle Scholar
  • 15 Hensleigh P A, Fainstat T. Corpus luteum dysfunction: serum progesterone levels in diagnosis and assessment of therapy for recurrent and threatened abortion.  Fertil Steril . 1979;  32 396-400
    PubMedGoogle Scholar
  • 16 Jordan J, Craig K, Clifton D K, et. al.  Luteal phase defect: the sensitivity and specificity of diagnostic methods in common clinical use. Fertil Steril . 1994;  62 54-62
    PubMedGoogle Scholar
  • 17 Castelbaum A J, Lessey B A. Corpus luteum defect: ``alloyed gold standard'' [letter].  Fertil Steril . 1995;  63 427-428
    PubMedGoogle Scholar
  • 18 Tulppala M, Bjorses U M, Stenman U H. Luteal phase defect in habitual abortion: progesterone in saliva.  Fertil Steril . 1991;  56 41-44
    PubMedGoogle Scholar
  • 19 Tho P T, Byrd J R, McDonough P G. Etiologies and subsequent reproductive performance of 100 couples with recurrent abortion.  Fertil Steril . 1979;  32 389-395
    PubMedGoogle Scholar
  • 20 Harger J H, Archer D F, Marchese S G, Murracca-Clemens M, Gawer K L. Etiology of recurrent pregnancy loss and outcome of subsequent pregnancies.  Obstet Gynecol . 1983;  62 574-581
    PubMedGoogle Scholar
  • 21 Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion.  Am J Obstet Gynecol . 1984;  148 140-146
    CrossrefPubMedGoogle Scholar
  • 22 Heinonen P K, Saarikoski S, Pystynen P. Reproductive performance of women with uterine anomalies.  Acta Obstet Gynaecol Scand . 1982;  61 157-162
    CrossrefPubMedGoogle Scholar
  • 23 Musich J R, Behrman S J. Obstetric outcome before and after metroplasty of the septate uterus.  J Reprod Med . 1984;  29 185-188
    PubMedGoogle Scholar
  • 24 Gray S E, Roberts D K, Franklin R R. Fertility after metroplasty of the septate uterus.  J Reprod Med . 1984;  29 185-188
    PubMedGoogle Scholar
  • 25 Buttram V C, Gibbons W E. Müllerian anomalies: a proposed classification (an analysis of 144 cases).  Fertil Steril . 1979;  32 40-46
    CrossrefPubMedGoogle Scholar
  • 26 Thompson J P, Smith R A, Welch J S. Reproductive ability after metroplasty.  Obstet Gynecol . 1966;  28 363-368
    PubMedGoogle Scholar
  • 27 Capraro V J, Chuang J T, Randall C L. Improved fetal salvage after metroplasty.  Obstet Gynecol . 1968;  31 94-103
    PubMedGoogle Scholar
  • 28 Rock J A, Murphy A A. Anatomic abnormalities.  Clin Obstet Gynecol . 1986;  29 886-911
    PubMedGoogle Scholar
  • 29 Daly D C, Witten C A, Soto-Albers C E, Riddick D H. Hysteroscopic metroplasty: surgical technique and obstetric outcome.  Fertil Steril . 1983;  39 623-628
    PubMedGoogle Scholar
  • 30 March C M, Israel R. Hysteroscopic management of recurrent abortion caused by septate uterus.  Am J Obstet Gynecol . 1987;  156 834-839
    PubMedGoogle Scholar
  • 31 Strassman E O. Fertility and unification of the double uterus.  Fertil Steril . 1966;  17 165-176
    PubMedGoogle Scholar
  • 32 Gros A, David A, Serr D M. Management of congenital malformation of the uterus: fetal salvage.  Acta Eur Fertil . 1974;  5 301-304
    PubMedGoogle Scholar
  • 33 Blum M. Prevention of spontaneous abortion by cervical suture of the malformed uterus.  Int Surg . 1977;  62 213-215
    PubMedGoogle Scholar
  • 34 Golan A, Langer R, Wexler S, Seveg E, Niv D, Menachem P D. Cervical cerclage: its role in the pregnant anomalous uterus.  Int J Fertil . 1990;  35 164-170
    PubMedGoogle Scholar
  • 35 Kaufman R H, Adam E, Binder G L, Gerthoffer E. Upper genital tract changes and pregnancy outcome in offspring exposed in utero to diethylstilbestrol.  Am J Obstet Gynecol . 1980;  137 299-308
    PubMedGoogle Scholar
  • 36 Ludmir J, Landon M B, Gabbe S C, Samuels P, Mennuti M T. Management of the DES-exposed pregnant patient: a prospective study.  Am J Obstet Gynecol . 1987;  157 665-669
    PubMedGoogle Scholar
  • 37 Iams J D, Johnson F F, Sonek J. Cervical competence as a continuum: a study of ultrasonographic cervical length and obstetric performance.  Am J Obstet Gynecol . 1995;  172 1097-1106
    Google Scholar
  • 38 March C M, Israel R. Gestational outcome following hysteroscopic lysis of adhesions.  Fertil Steril . 1981;  36 455-459
    PubMedGoogle Scholar
  • 39 Schenker J G, Margalioth E J. Intrauterine adhesions: an updated appraisal.  Fertil Steril . 1982;  37 593-610
    CrossrefPubMedGoogle Scholar
  • 40 Stray-Pedersen B, Eng J, Reikvam T M. Uterine T-mycoplasma colonization in reproductive failure.  Am J Obstet Gynecol . 1978;  130 307-311
    PubMedGoogle Scholar
  • 41 Wilson W A, Gharavi A E, Koike T. International consensus statement on preliminary classification criteria for antiphospholipid syndrome: report of an international workshop.  Arthritis Rheum . 1999;  42 1309-1311
    CrossrefPubMedGoogle Scholar
  • 42 Silver R M, Porter T F, van Leeuwen I, Jeng G, Scott J R, Branch D W. Anticardiolipin antibodies: clinical consequences of ``low titers''.  Obstet Gynecol . 1996;  87 494-500
    CrossrefPubMedGoogle Scholar
  • 43 Branch D W, Silver R M, Pierangelli S S, van Leeuwen I, Harris E N. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome.  Obstet Gynecol . 1997;  89 549-555
    CrossrefPubMedGoogle Scholar
  • 44 Oshiro B T, Silver R M, Scott J R, Yu H, Branch D W. Antiphospholipid antibodies and fetal death.  Obstet Gynecol . 1996;  87 489-493
    CrossrefPubMedGoogle Scholar
  • 45 Branch D W, Scott J R. Clinical implications of anti-phospholipid antibodies: the Utah experience. In: Harris EN, Exner T, Hughes GRV, Asherson RA, eds. Phospholipid-Binding Antibodies Boca Raton, FL: CRC Press 1991: 335-346
    Google Scholar
  • 46 Out H J, Bruinse H W, Christianens G M L C. Prevalence of antiphospholipid antibodies in patients with fetal loss.  Ann Rheum Dis . 1991;  50 553-557
    CrossrefPubMedGoogle Scholar
  • 47 Parazzini F, Acaia B, Faden D, Lovotti M, Marelli G, Cortelazzo S. Antiphospholipid antibodies and recurrent abortion.  Obstet Gynecol . 1991;  77 854-858
    PubMedGoogle Scholar
  • 48 Parke A L, Wilson D, Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant.  Arthritis Rheum . 1991;  34 1231-1235
    PubMedGoogle Scholar
  • 49 Branch D W, Silver R M, Blackwell J L, Reading J C, Scott J R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience.  Obstet Gynecol . 1992;  80 614-620
    PubMedGoogle Scholar
  • 50 Rosove M H, Tabsh K, Wasserstrum N, Howard P, Hahn B H, Kalunian K C. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies.  Obstet Gynecol . 1990;  75 630-634
    PubMedGoogle Scholar
  • 51 Cowchock F S, Reece E A, Balaban D. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone to low-dose heparin treatment.  Am J Obstet Gynecol . 1992;  166 1318-1323
    PubMedGoogle Scholar
  • 52 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnancy in women with recurrent miscarriage associated with phospholipid antibodies.  BMJ . 1997;  314 253-257
    CrossrefPubMedGoogle Scholar
  • 53 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol . 1996;  35 1584-1589
    PubMedGoogle Scholar
  • 54 Clark A L, Branch D W, Silver R M, Harris E N, Pierangeli S, Spinnato J A. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy.  Obstet Gynecol . 1999;  93 437-441
    CrossrefPubMedGoogle Scholar
  • 55 Branch D W, Peaceman A M, Druzin M. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy.  Am J Obstet Gynecol . 2000;  182 122-127
    CrossrefPubMedGoogle Scholar
  • 56 Preston F E, Rosendaal F R, Walker I D. Increased fetal loss in women with heritable thrombophilia.  Lancet . 1996;  348 913-916
    CrossrefPubMedGoogle Scholar
  • 57 Wouters M G, Boers G H, Blom H J. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss.  Fertil Steril . 1993;  60 820-825
    PubMedGoogle Scholar
  • 58 Schved J F, Gris J C, Neveu S. Factor XII congenital deficiency and early spontaneous abortion.  Fertil Steril . 1989;  52 335-336
    PubMedGoogle Scholar
  • 59 Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism.  N Engl J Med . 1994;  330 517-522
    CrossrefPubMedGoogle Scholar
  • 60 Bertina R M, Koeleman B P, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
    CrossrefPubMedGoogle Scholar
  • 61 Branch D W. Immunologic aspects of pregnancy loss: alloimmune and autoimmune considerations. In: Reece EA, Hobbins JC, Mahoney MJ, Petrie RH, eds. Medicine of the Fetus and Mother Philadelphia: JB Lippincott 1992: 217-233
    Google Scholar
  • 62 Kutteh W H, Stovall D W, Scott J R. The immunologic diagnosis and treatment of recurrent pregnancy loss.  Infertil Reprod Med Clin North Am . 1997;  8 267-287
    PubMedGoogle Scholar
  • 63 Coulam C B, Clark D A, Collins J, Scott J R. Worldwide collaborative observational study and meta-analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion.  Am J Reprod Immunol . 1994;  23 55-72
    PubMedGoogle Scholar
  • 64 Jeng G T, Scott J R, Burmeister L F. A comparison of meta-analytic results using literature versus individual patient data.  JAMA . 1995;  274 830-836
    CrossrefPubMedGoogle Scholar
  • 65 Ober C, Karrison T, Odem R R. Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial.  Lancet . 1999;  354 365-369
    CrossrefPubMedGoogle Scholar
  • 66 Coulam C B, Krysa L, Stern J J, Bustillo M. Intravenous immunoglobulin for the treatment of recurrent pregnancy loss.  Am J Reprod Immunol . 1995;  34 333-338
    PubMedGoogle Scholar
  • 67 The German RSA/IVIG Group. Intravenous immune globulin in the prevention of recurrent miscarriage.  Br J Obstet Gynaecol . 1994;  101 1072-1077
    PubMedGoogle Scholar
  • 68 Christiansen O B, Mathiesen O, Husth M. Placebo controlled trial for treatment of unexplained secondary recurrent abortions and recurrent late spontaneous abortions with iv immunoglobulin.  Hum Reprod . 1995;  10 2690-2694
    PubMedGoogle Scholar
  • 69 Mowbray S F, Gibbons C, Liddell H. Controlled trial of treatment of recurrent spontaneous abortion by immunization with paternal cells.  Lancet . 1985;  1 941-943
    PubMedGoogle Scholar
  • 70 Ho H N, Gill T H, Hsieh H J, Jiang J J, Lee T Y, Hsieh C Y. Immunotherapy for recurrent spontaneous abortions in a Chinese population.  Am J Reprod Immunol . 1991;  25 10-15
    PubMedGoogle Scholar
  • 71 Tupper C, Weil R J. The problem of spontaneous abortion.  Am J Obstet Gynecol . 1962;  83 421-429
    PubMedGoogle Scholar
  • 72 Stray-Pedersen B, Stray-Pedersen S. Recurrent abortion: the role of psychotherapy. In: Beard RW, Sharp F, eds. Early Pregnancy Loss London: Springer-Verlag 1988: 433-440
    Google Scholar